Učinak topikalno primijenjenog nearomatskog (NAVS) naftalana u liječenju oralnog lihena planusa i rekurentnih aftoznih ulceracija

doctoral thesis

• Title (english): TOPICAL NON-AROMATIC VERY RICH IN STERANES (NAVS) NAPHTHALAN FOR THE TREATMENT OF ORAL LICHEN PLANUS AND RECURRENT APHTHOUS STOMATITIS
• Author: Ana Andabak Rogulj
• Mentor: Ivan Alajbeg (mentor)
• Committee member: Vanja Vučićević-Boras (predsjednik povjerenstva)
• Committee member: Jasna Lovrić (član povjerenstva)
• Committee member: Jozsef Petrik (član povjerenstva)
• Committee member: Mislav Jurin (član povjerenstva)
• Committee member: Vlaho Brailo (član povjerenstva)
• Granter: University of Zagreb; School of Dental Medicine; (Department of Oral Medicine); Zagreb
• Defense date and country: 2014-09-19, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Dental Medicine; Oral Medicine
• Universal decimal classification (UDC): 616.31 - Stomatology

Abstract

Uvod: NAVS Nearomatski visokosteranski naftalan prirodno je mineralno ulje dobiveno složenim nizom postupaka separacije i rafinacije čime je očuvana steranska struktura NAVS-a kojoj se pripisuju ljekovita svojstva. Svrha istraživanja bila je ispitati učinkovitost NAVS-a u liječenju oralnog lihena planusa (OLP) i rekurentnih aftoznih ulceracija (RAU) te potvrditi sigurnost njegove primjene. Materijali i metode: Istraživanje je provedeno kao randomizirana dvostruko-slijepa studija na pedeset i sedam ispitanika (30 OLP, 27 RAU). Primjena NAVS-a 3x dnevno tijekom 28 dana provedena je u ispitnoj skupini, a 0,05% betametazon dipropionata u kontrolnoj skupini. Klinički intenzitet bolesti (REU) bilježen je u ispitanika s OLP-om. Broj i promjer lezija u bolesnika s RAU bilježen je na 0., 3. i 5. dan. Intenzitet boli i nelagode procjenjivan je korištenjem vizualne analogne skale (VAS) i upitnikom OHIP-14, prije i nakon liječenja. Rezultati: Veće smanjenje REU zabilježeno je u NAVS skupini (NAVS 67,21%, betametazon 66,30%), iako ne statistički značajno (p=0,4421). Nije bilo statistički značajne razlike u smanjenju OHIP-14 između NAVS (74,38%) i betametazon skupine (67,55%) (p=0,8191). Smanjenje VAS-a za NAVS iznosilo je 96,29%, a za betametazon 93,66% (p=0,3722). Nije bilo statistički značajne razlike između skupina u smanjenju broja (3. dan p=0,48; 5. dan p=0,75) i veličine lezija (3. dan p=0,40; 5. dan p=0,83) u ispitanika s RAU. Zabilježeno je smanjenje VAS-a i OHIP-14 u obje skupine ispitanika 8. dana po završenoj terapiji, međutim razlika nije bila statistički značajna (VAS p=0,59; OHIP-14 p=0,69). Zaključak: NAVS je uspješno smanjio kliničke znakove i simptome OLP-a, te broj, veličinu lezija i simptome u bolesnika s RAU.

Abstract (english)

Introduction: "Non-aromatic Very rich in Steranes" (NAVS) naphtalan is a natural mineral oil, produced by various methods of separation, with a preserved sterane structure which has healing properties. The purpose of this study was to evaluate the effectiveness of NAVS in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Material and Methods: A randomized, double-blind trial was designed. Fifty seven patients (30 OLP, 27 RAS) were randomized into two groups to receive NAVS or 0,05%-betamethasone dipropionate in adhesive paste 3x daily for 28 days. The severity of the OLP lesions (REU) was objectively scored. The number and the diameter of RAS lesions were assessed on days 0, 3 and 5. The intensity of the pain/discomfort was determined using a visual analogue scale (VAS) and OHIP-14-questionnaire before and after the therapy. Results: Greater REU reduction was observed in NAVS group (NAVS 67,21%, betamethasone 66,30%), although it was not statistically significant (p=0,4421). No statistically significant differences in the reduction of the OHIP-14 between NAVS (74,38%) and betamethasone group (67,55%) were observed (p=0,8191). VAS reduction for NAVS was 96,29% and for betamethasone 93,66% (p=0,3722). There were no statistically significant differences between the two groups in reduction of number (day 3. p=0,48; day 5. p=0,75) and lesion diameter (day 3. p=0,40; day 5. p=0,83) in RAS patients. VAS and OHIP-14 reduction was observed in both groups 8 days after the completion of therapy, but the difference was not statistically significant (RAS p=00,59; OHIP-14 p=0,69). Conclusion: NAVS has successfully reduced the clinical signs and symptoms of OLP. It has reduced the number, diameter and symptoms in patients with RAS.

• Keywords: NAVS naftalan; topikalna terapija; oralni lihen planus; rekurentne aftozne ulceracije
• Keywords (english): NAVS Naphthalan; topical treatment; oral lichen planus; recurrent aphthous stomatitis
• Language: croatian
• URN:NBN: urn:nbn:hr:127:399800
• Study programme: Title: dental medicine; Study programme type: university; Study level: postgraduate; Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo, polje dentalna medicina (doktor/doktorica znanosti, područje biomedicine i zdravstvo, polje dentalna medicina)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2017-02-21 10:04:42